

**Measures and Guidelines for Extraordinary General Meeting of Trust Unitholders No. 1/2022
Under the Situation of Coronavirus Disease 2019 (COVID-19) Outbreak, and COVID-19 Screening Form**

Due to the Circumstance of Coronavirus Disease 2019 (COVID-19) Outbreak, the Company sincerely care about safety and health of the trust unitholders or a proxy. Therefore, the Company has formulated the Measures and Guidelines for Extraordinary General Meeting of Trust Unitholders No. 1/2022 Under the Situation of Coronavirus Disease 2019 (COVID-19) Outbreak as follows:

1. Trust unitholders are encouraged to consider granting Proxy to the Company's Independent Director or Trustee's staff to attend the meeting instead of participating in persons due to the fact that the meeting is deemed to be a public gathering, which is a risk factor of outbreak. In this regard, trust unitholders can grant a proxy to the Company's Independent Director or Trustee's staff to attend the Meeting (Details of Proxy Forms attached with Invitation to the Extraordinary Trust Unitholders' Meeting as appeared in **Enclosure 10**).
2. In case of the trust unitholders who wish to attend the Meeting in person or grating a proxy who is not the Company's Independent Director or Trustee's staff, the Company would like to request trust unitholder or proxy's cooperation to strictly follow the Company's Measures and Guidelines for Extraordinary General Meeting of Trust Unitholders No. 1/2022 to prevent and minimize the risk of COVID-19 virus spreading as follows:
 - 2.1 Every person attending the Trust Unitholders' Meeting must wear a facemask at all times, as well as appropriately maintain social distancing from other persons.
 - 2.2 The Company will organize the meeting venue to avoid crowded of trust unitholders in meeting area with appropriate social distancing of approximately 1 meter in various areas, such as screening points, document-checking points and registration counters, as well as limiting number of people in elevator in each round and constant providing cleaning of equipment and touchable area by crowded with cleanser and alcohol at least 2 times per day. In addition, the Company will arrange a public media to instruct the prevention of COVID-19 spreading to inform trust unitholders.
 - 2.3 The meeting attendees are required to fill out the COVID-19 Screening Form attached with this document and procure to show to the Company at the registration point of the meeting. If the result of the Screening Form shows that the meeting attendees demonstrate high risks of infection, **the Company reserves the right to not allow that trust unitholder or that proxy to enter the Extraordinary General Meeting of Trust Unitholders No. 1/2022**. In addition, the Company suggest the trust unitholders to appoint the Company's Independent Director or Trustee's staff as their proxies to attend the meeting. In this regard, the Company's officer will provide documentations for your convenience. (Details of Proxy Forms attached with Invitation to Extraordinary General Meeting of Trust Unitholders No. 1/2022 set out in **Enclosure 10**). The meeting attendees must not to conceal their health information or traveling record to the Company.
 - 2.4 The Company shall ensure a screening process for the COVID-19 infection before entering the meeting venue by checking the Antigen Test Kit (ATK) negative result during the past 72 hours. In this regard, given that the Company shall not provide the ATK at the meeting venue, the Company would like to ask for the meeting attendees'

cooperation to take the test before attending the meeting. In addition, the Company shall provide body-temperature screening before entering the venue of the meeting. The meeting attendees who have a body temperature of 37.5 degrees celsius or higher or have risky symptoms such as fever, cough, sore throat, sneezing, runny nose, shortness of breath, or do not follow the recommendations from the medical officer; **the Company reserves the rights to not allow that trust unitholder or that proxy to enter the Extraordinary General Meeting of Trust Unitholders No. 1/2022.** In addition, the Company suggest the trust unitholders to appoint the Company's Independent Director or Trustee's staff as their proxy to attend the Meeting. In this regard, the Company's officer shall provide documentations for your convenience. (Details of Proxy Forms attached with Invitation to the Extraordinary Trust Unitholders' Meeting shall be as appeared in **Enclosure 10**). The meeting attendees must not conceal their health information or traveling record to the Company.

- 2.5 The Company shall provide medical first aid point for a preliminary medical treatment that isolates the meeting attendees who have risky symptoms such as fever, cough, sore throat, sneezing, runny nose, or shortness of breath from an area of the meeting venue and shall provide surgical mask and transportation to the hospital for medical care.
3. **The Company reserves the right to not allow any trust unitholders or any proxies who do not pass the health screening or do not show the COVID-19 Screening Form to attend the Extraordinary General Meeting of Trust Unitholders No. 1/2022.**
4. The meeting attendees who passed the health screening are requested to put on a sticker and wear a facemask prepared by themselves at all times during the Meeting and clean hands by using the alcohol-based hand sanitizer gel, prepared by themselves and provided by the Company around the meeting areas, before and after the meeting as well as before entering in and out of the area of the meeting venue.
5. The meeting attendees who passed the health screening are requested to be seated. After the registration procedure, trust unitholders or proxies will be assigned a seating number and are required to sit as specified for the purpose of disease prevention or following up in case of any circumstances. Seats are not allowed to be moved to keep appropriate distance whereby the Company shall arrange the seats in the area of the meeting which will be approximately 1 meter distancing from one another, and in order to comply with regulations issued by official authorities, resulting to the limited number of available seats in the meeting venue to be significantly decreased. If the seats are fully occupied, the trust unitholders shall not be allowed to enter the area of the meeting. Therefore, the Company hereby suggest the trust unitholders appoint the Company's Independent Director or Trustee's staff as their proxies to attend the meeting; in this regard, the Company's staff shall provide documentation for your convenience. (Details of Proxy Forms attached with Invitation to the Extraordinary Trust Unitholders' Meeting shall be as appeared **in Enclosure 10**).
6. Should the Company notice any of the meeting attendees having risky symptoms such as fever, cough, sore throat, sneezing, runny nose, or shortness of breath, the Company reserve the right to request such meeting attendees to leave an area of the meeting.

7. For the meeting to be concisely arranged, should the trust unitholders or the proxies who have further questions at the meeting, the Company hereby request such persons to write their questions on prepared paper and put them in the inquiry box instead of inquiry through the microphone. The Company's staff will prepare papers and pens during the meeting. In this regard, the Company shall summarize questions and answers in the minutes of the meeting.
8. The Company will provide snacks, but the Company would like to request the trust unitholders or the proxies to absolutely refrain from eating in the meeting area in order to mitigate risks of the COVID-19 spreading.

Furthermore, the Company may change any procedures in compliance with measures from the government or regulations issued by official authorities, which may change later. In addition, the Company reserves the right to inform any procedures changes through any channel as the Company deems appropriate. In this regard, the compliance with the above measures and guidelines may cause a delay in the screening and registration of the meeting. The Company hereby would like to apologize for any inconvenience and sincerely thank all trust unitholders, and hopefully, receive your kind cooperation on this matter.

แบบคัดกรองโรคติดเชื้อไวรัสโคโรนา 2019 (COVID-19)

ก่อนประชุมวิสามัญผู้ถือหุ้นหน่วยทรัสต์ ครั้งที่ 1/2565 ในวันที่ 15 กรกฎาคม 2565

ณ ห้องประชุมสุรศักดิ์ 2 - 3 ชั้น 11 โรงแรมอีสติน แกรนด์ สาทร เลขที่ 33/1 ถนนสาทรใต้ ยานนาวา

สาทร กรุงเทพมหานคร 10120

และ/หรือบริเวณที่ทางบริษัทฯ จะได้จัดเตรียมไว้

Coronavirus Disease 2019 (COVID-19) Screening Form

Before attending Extraordinary Meeting of Trust Unitholders No. 1/2022 on 15 July 2022

At Surasak Meeting Room 2-3, 11th floor, Eastin Grand Hotel Sathorn, No. 33/1 South Sathorn Rd,

Khwaeng Yan Nawa, Bangkok 10120

and/or the area provided by the Company

บริษัทฯ ขอความร่วมมือท่านให้ข้อมูลที่ถูกต้องเป็นความจริง เพื่อประโยชน์ในการป้องกันการแพร่ระบาดของ
โรคติดเชื้อไวรัสโคโรนา 19 (COVID-19)

We need your corporation in providing the most accurate and truthful information for effective
prevention of the spreading of the Coronavirus Disease 2019 (COVID-19).

ชื่อ – สกุล (Name-Surname) _____

หมายเลขโทรศัพท์ (Mobile Phone Number) _____

ที่อยู่ติดต่อได้ (Contact Address) _____

ท่านมีไข้หรือไม่? (≥ 37.5 °C) Do you have a fever? (≥ 37.5 °C) ใช่ (Yes) ไม่ใช่ (No)

1. ท่านมีอาการดังต่อไปนี้ หรือไม่? Do you have any of these symptoms?

ไอ Cough ใช่ (Yes) ไม่ใช่ (No)

เจ็บคอ Sore throats ใช่ (Yes) ไม่ใช่ (No)

น้ำมูกไหล Runny nose ใช่ (Yes) ไม่ใช่ (No)

หอบเหนื่อย Shortness of breath ใช่ (Yes) ไม่ใช่ (No)

2. ท่านมีประวัติการเดินทางมาจากต่างประเทศ หรือมาจากพื้นที่ที่มีการระบาดของ COVID-19 ใน 14
วันที่ผ่านมาหรือไม่?

Have you traveled / transited from any countries except Thailand or areas with COVID-19 outbreak within the past 14 days?

ใช่ (Yes) มาจากประเทศ / พื้นที่ (I have traveled to): _____

ไม่ใช่ (No)

3. ท่านมีประวัติสัมผัสใกล้ชิดกับผู้ป่วยหรือผู้ที่ต้องสงสัยว่าติด COVID-19 หรือไม่?

Have you been in physical contact with patients or a person who is suspected to have COVID-19?

ใช่ (Yes)

ไม่ใช่ (No)

หมายเหตุ หากพบว่าท่านมีไข้ (≥ 37.5 °C) หรือมีอาการอย่างใดอย่างหนึ่งตามที่บริษัทฯ ระบุไว้ข้างต้น หรือมีประวัติเดินทางมาจากต่างประเทศ หรือพื้นที่ที่มีการแพร่ระบาดของโรคติดเชื้อไวรัสโคโรนา 19 (COVID-19) หรือมีประวัติสัมผัสใกล้ชิดกับผู้ป่วยที่ต้องสงสัยการติด COVID-19 บริษัทฯ ขออนุญาตให้ท่านผู้ถือหน่วยทรัสต์ มอบฉันทะให้กรรมการอิสระของบริษัทฯ หรือพนักงานของทรัสต์แทนการเข้าร่วมประชุมด้วยตนเอง (รายละเอียดหนังสือมอบฉันทะที่แนบมากับหนังสือเชิญประชุมครั้งนี้ ดังมีรายละเอียดปรากฏตาม สิ่งที่ส่งมาด้วย 10) และเดินทางกลับ พร้อมปฏิบัติตามคำแนะนำของกระทรวงสาธารณสุข

Remark If you have a fever (≥ 37.5 °C); or any symptoms which indicates above; or traveled / transited from any countries except Thailand or the COVID-19 outbreak areas; or have been in contact with suspected COVID-19 patients, the Company would like to kindly ask for your cooperation in giving proxy to an independent director of the Company or Trustee's staff to attend the meeting on your behalf (details of the proxy is provided in Enclosure 10). Then you may then return safely to your resident and follow the guideline of Ministry of Public Health.